Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06512181 · ClinicalTrials.gov registry record · NA
Uterine Preservation in the Management of Placenta Accreta Spectrum Disorders
A NA study of Placenta Accreta Spectrum, sponsored by University of Pennsylvania.
- Recruiting
- Registry status
- NA
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT06512181: Recruiting NA study of Placenta Accreta Spectrum, sponsored by University of Pennsylvania.
NCT06512181 is a NA study of Placenta Accreta Spectrum that is actively recruiting participants, run by University of Pennsylvania. The registered enrollment target is 15 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06512181, a NA study of Placenta Accreta Spectrum, is actively recruiting participants, sponsored by University of Pennsylvania.
- RECRUITING
- Registry status
- NA
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
This study for the conservative management of placenta accreta spectrum disorders (PAS), which are a major cause of maternal morbidity and mortality. The most common management strategy for PAS in the United States is a preterm cesarean-hysterectomy. However, accumulating data show that conservative management is safer and is preferred by some patients. In selected participants (n=15) who desire uterine preservation, the investigators provide the option of conservative management, which will be defined as leaving the placenta in the uterus after delivery of the infant. This is a single-arm single-site pilot study where all participants will be carefully monitored during a standard postpartum inpatient stay and with outpatient follow-up until the uterus is empty.
Primary Outcome
Percent of participants who undergo a hysterectomy
Conditions Studied
Interventions
- OTHER Conservative/Expectant Management
Study Locations (1)
Pennsylvania
- Hospital of the University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2025-04-21 |
| Est. Completion | 2030-12-31 |
| Phase | NA |
What NCT06512181 shows while recruiting
NCT06512181 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Placenta Accreta Spectrum appearing as the primary indexed condition, and to 1 intervention - of which Conservative/Expectant Management is the first listed.
NCT06512181 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06512181 about?
NCT06512181 is a clinical study titled "Uterine Preservation in the Management of Placenta Accreta Spectrum Disorders". This study for the conservative management of placenta accreta spectrum disorders (PAS), which are a major cause of maternal morbidity and mortality. The most common management strategy for PAS in the United States is a preterm cesarean-hysterectomy. However, accumulating data show that conservative...
What is the current status of trial NCT06512181?
This trial is currently recruiting. It is a NA study. The enrollment target is 15 participants. The study started on 2025-04-21. Estimated completion is 2030-12-31.
What conditions does trial NCT06512181 study?
This clinical trial studies the following conditions: Placenta Accreta Spectrum.
What interventions are being tested in trial NCT06512181?
The interventions under investigation include: Conservative/Expectant Management (OTHER).
Who is sponsoring clinical trial NCT06512181?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06512181 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06512181's enrollment target sits among peer trials
15 1881st of 2000 higher than 92 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI